AU2022273186A1 - Medium molecular weight heparin for use in the treatment of endotheliopathy - Google Patents

Medium molecular weight heparin for use in the treatment of endotheliopathy Download PDF

Info

Publication number
AU2022273186A1
AU2022273186A1 AU2022273186A AU2022273186A AU2022273186A1 AU 2022273186 A1 AU2022273186 A1 AU 2022273186A1 AU 2022273186 A AU2022273186 A AU 2022273186A AU 2022273186 A AU2022273186 A AU 2022273186A AU 2022273186 A1 AU2022273186 A1 AU 2022273186A1
Authority
AU
Australia
Prior art keywords
molecular weight
medium molecular
weight heparin
vwf
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022273186A
Other languages
English (en)
Inventor
Pervinder Singh Bhogal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycos Biomedical Ltd
Original Assignee
Glycos Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycos Biomedical Ltd filed Critical Glycos Biomedical Ltd
Publication of AU2022273186A1 publication Critical patent/AU2022273186A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022273186A 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy Pending AU2022273186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106972.9 2021-05-14
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin
PCT/EP2022/063222 WO2022238587A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Publications (1)

Publication Number Publication Date
AU2022273186A1 true AU2022273186A1 (en) 2024-01-04

Family

ID=76550734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273186A Pending AU2022273186A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Country Status (8)

Country Link
US (1) US20240245718A1 (https=)
EP (1) EP4337225A1 (https=)
JP (1) JP2024517355A (https=)
CN (1) CN117915923A (https=)
AU (1) AU2022273186A1 (https=)
CA (1) CA3219993A1 (https=)
GB (1) GB202106972D0 (https=)
WO (1) WO2022238587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin
GB202407360D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
WO2022016098A1 (en) * 2020-07-17 2022-01-20 Xostem Ip, Inc. Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes

Also Published As

Publication number Publication date
GB202106972D0 (en) 2021-06-30
EP4337225A1 (en) 2024-03-20
US20240245718A1 (en) 2024-07-25
WO2022238587A1 (en) 2022-11-17
JP2024517355A (ja) 2024-04-19
CN117915923A (zh) 2024-04-19
CA3219993A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Best et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
US20240245718A1 (en) Medium molecular weight heparin for use in the treatment of endotheliopathy
Nilsson et al. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies
Jankowska-Sanetra et al. Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic
WO2024105271A1 (en) Preparation of medium molecular weight heparin
Lunetta et al. Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease
Nespola et al. Treatment-resistant acute upper limb ischemia in a patient with systemic lupus erythematous and concomitant SARS-CoV-2 infection: a case report
Dixon et al. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery
Tsipis et al. Novel oral anticoagulants in peripheral arterial and coronary artery disease
WO2025106117A1 (en) Medium molecular weight heparin
HK40109661A (zh) 用於治疗内皮病的中分子量肝素
AU2023381620A1 (en) Preparation of medium molecular weight heparin
Armstrong et al. Pharmacology of hemostasis and thrombosis
Kon et al. Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition
WO2025245445A1 (en) Functionalised medium molecular weight heparin
Westerhout et al. Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
Rice et al. Argatroban therapy in heparin-induced thrombocytopenia
Goubran et al. Coagulation and Anticoagulants
Özkan et al. Acute complications of hemodialysis
Oldgren et al. Xa inhibition and coagulation activity—the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals
Chintala et al. 5063 JNJ-9375, a novel exosite 1 thrombin inhibitor does not increase bleeding in a spontaneous gastrointestinal (GI) bleeding model in mice with a mutation of the Adenomatous polyposis coli (Apc) gene
Stefano Barco et al. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
Mousa Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin
Permana et al. The Efficacy of Albumin Channa Striata Extract Administration in Stabilizing PAI-1 and Platelet Levels in Septic Patients: A Randomized Control Trial Study. Open Access Maced J Med Sci. 2022 Oct 28; 10 (B): 2313-2318
Young Wang et al. Stuck Between a Rock and a Hard Place: Anticoagulation in End-Stage Kidney Disease Patients With Atrial Fibrillation